

Applicant: Warren J. Scherer
Application Serial No.: 10/626,037
Filing Date: July 23, 2003
Docket No.: 512-160
Page 2 of 11

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions of listing of claims, and listing of claims in the application.

Listing of Claims

1. (Currently Amended) A method of reducing cutaneous facial flushing caused by menopause-associated hot flashes in a human in need thereof, the method comprising topically administering locally to the skin of the human a composition comprising at least one selective α_2 adrenergic receptor agonist admixed with a dermatologically acceptable carrier, in an amount effective to reduce the cutaneous facial flushing, wherein the selective α_2 adrenergic receptor agonist is at least two-fold to fifty-fold more selective for the α_2 adrenergic receptor as compared to clonidine and wherein the selective α_2 adrenergic receptor agonist acts locally.
2. (Previously Presented) The method of claim 1, wherein the composition contains at least one (2-imidazolin-2-ylamino) quinoxaline derivative or an acidic salt thereof.
- 3-10. (Cancelled)
11. (Original) The method of claim 2, wherein the composition further comprises an agent, or combination of agents, selected from the group consisting of antibacterial agents, anthelmintic agents, antioxidant agents, steroid anti-inflammatory agents, non-steroidal anti-inflammatory agents, antiangiogenic agents, and derivatives of retinoic acid.
12. (Original) The method of claim 1, wherein the composition further comprises an agent, or combination of agents, selected from the group consisting of antibacterial agents, anthelmintic agents, antioxidant agents, steroid anti-inflammatory agents, non-steroidal

Applicant: Warren J. Scherer
Application Serial No.: 10/626,037
Filing Date: July 23, 2003
Docket No.: 512-160
Page 3 of 11

anti-inflammatory agents, antiangiogenic agents, and derivatives of retinoic acid.

13-33. (Cancelled)

34. (Previously Presented) The method of claim 1, wherein the selective α_2 adrenergic receptor agonist is at least seven-fold to twelve-fold more selective for the α_2 adrenergic receptor as compared to clonidine.

35. (Previously Presented) The method of claim 1, wherein the composition is administered to the skin of the human.

36. (Currently Amended) A method of treating facial flushing associated with menopause-associated hot flashes in a human in need thereof, the method comprising topically administering a composition comprising an effective amount of brimonidine tartrate and a dermatologically acceptable carrier locally to facial skin of~~to the site of the facial flushing on~~ the human wherein the brimonidine acts locally.